問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

5239Cases

2011-05-01 - 2013-06-30

Phase III

A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (incl. 24 weeks of preceding trial) as monotherapy or with different back-ground therapies in patients with type 2 diabetes mellitus previously completing trial 1245.19, 1245,20 or 1245.23.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    BI 10773

Participate Sites
9Sites

Terminated9Sites

2014-02-01 - 2016-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-12-13 - 2016-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-06-01 - 2014-12-31

Phase III

A phase III randomised, double-blind and placebo-controlled study of BI 207127 NA in combination with faldaprevir and ribavirin for chronic genotype 1b hepatitis C virus infection in an extended population of treatment naïve patients that includes those ineligible to receive peginterferon

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 207127 , Faldaprevir (BI 201335 NA)

Participate Sites
10Sites

Terminated10Sites

2010-02-01 - 2011-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2012-09-14 - 2016-12-31

Phase III

A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in treatment-naïve and prior relapser patients with genotype 1 chronic hepatitis C infection.

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BI 201335

Participate Sites
9Sites

Terminated9Sites

2012-12-03 - 2015-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-01-01 - 2015-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-01-01 - 2013-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-01-01 - 2013-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 500 501 502 503 504 524
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB